Journal of Inborn Errors of Metabolism and Screening (Sep 2018)

Understanding the Early Presentation of Mucopolysaccharidoses Disorders

  • Lorne Clarke MD,
  • Carolyn Ellaway MBBS, PhD,
  • Helen E. Foster MD, MBBS,
  • Roberto Giugliani MD, PhD,
  • Cyril Goizet MD, PhD,
  • Sarah Goring MSc,
  • Sara Hawley MSc,
  • Elaina Jurecki MS, RD,
  • Zaeem Khan MPH, BSc,
  • Christina Lampe MD,
  • Ken Martin MD,
  • Suzanne McMullen MHA, BSc,
  • John J. Mitchell MD,
  • Fathima Mubarack MSc, MHA,
  • H. Serap Sivri MD,
  • Martha Solano Villarreal MD, PhD,
  • Fiona J. Stewart MB, BS,
  • Anna Tylki-Szymanska MD, PhD,
  • Klane White MD, MSc,
  • Frits Wijburg MD, PhD

DOI
https://doi.org/10.1177/2326409818800346
Journal volume & issue
Vol. 7

Abstract

Read online

As therapies are developed for rare disorders, challenges of early diagnosis become particularly relevant. This article focuses on clinical recognition of mucopolysaccharidoses (MPS), a group of rare genetic diseases related to abnormalities in lysosomal function. As quality of outcomes with current therapies is impacted by timing of intervention, minimizing time to diagnosis is critical. The objective of this study was to characterize how, when, and to whom patients with MPS first present and develop tools to stimulate earlier recognition of MPS. A tripartite approach was used, including a systematic literature review yielding 194 studies, an online physician survey completed by 209 physicians who described 859 MPS cases, and a global panel of MPS experts who distilled the findings. Red flag signs/symptoms were identified for cardiology, pediatric neurology, otorhinolaryngology, rheumatology, orthopedics, pediatrics, and general medicine and converted into simple, specialty-specific tools intended to facilitate early diagnosis of MPS, enabling improved patient outcomes.